Sugi Predict

Sugi Predict / Compounds / SCHEMBL20069713

SCHEMBL20069713

SCHEMBL20069713

CC(C)COC(=O)NC1(CN(C)C)CCN(C)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 4/20 0.42
▸ GHSR Q92847 2/20 0.35
▸ HSD11B1 P28845 1/20 0.33
▸ TSHR P16473 3/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ DRD2 P14416 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ FSHR P23945 2/20 0.32
▸ ABL1 P00519 1/20 0.32
▸ LCK P06239 1/20 0.32
▸ HCK P08631 1/20 0.32
▸ KIT P10721 1/20 0.32
▸ SRC P12931 1/20 0.32
▸ PDGFRA P16234 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ TEK Q02763 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20147514 0.88 RET (0.42) RETGHSRHSD11B1TSHRKDM4E
SCHEMBL20069723 0.81 RET (0.42) RETTSHRALDH1A1FSHR
SCHEMBL20069525 0.80 RET (0.41) RETALDH1A1SMN1; SMN2
SCHEMBL20069155 0.80 RET (0.38) RETGHSRHSD11B1TSHRKDM4E
SCHEMBL20069722 0.80 RET (0.43) RET
SCHEMBL20069702 0.79 RET (0.35) RETGHSRKDM4EDRD2SMN1; SMN2
SCHEMBL20068984 0.78 RET (0.42) RETKDM4EMAPTHSD17B10SMN1; SMN2
SCHEMBL20069711 0.77 RET (0.40) RET
SCHEMBL20068870 0.77 RET (0.40) RETALDH1A1SMN1; SMN2
SCHEMBL20158431 0.72 RET (0.39) RETKDM4EALDH1A1HSD17B10RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 — — US disclosed
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 — — US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 — — US disclosed
WO-2018071454-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885GHSR 1829/4885HSD11B1 2886/4885
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885GHSR 1829/4885HSD11B1 2886/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885GHSR 1829/4885HSD11B1 2886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.